Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.125
Bid: 17.75
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.75 (4.225%)
Open: 18.125
High: 18.125
Low: 18.125
Prev. Close: 18.125
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further sales expansion in Asia

6 Jul 2021 07:00

RNS Number : 2351E
OptiBiotix Health PLC
06 July 2021
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Further sales expansion in Asia

New Exclusive Distribution deal for CholBiome® in South Korea

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered a exclusive disbution deal with INSCOBEE INC ("Inscobee") for CholBiome® in the Republic of Korea.

 

Inscobee was established in 1970 and is listed on Korea's major stock market KOSPI since 1985. Its business activities consist of four fast growing business fields: the Smart grid, Mobile Virtual Network Operation, Cosmetics, and Bio-Tech, which includes its pharmaceutical, neutraceuticals, and supplement products with distribution in domestic and overseas markets. Inscobee's group turover was 57.8 billion Korean Won (USD 52.2m) last year and they are curently focused on expanding the health supplement area of their business.

 

Inscobee sell and promote nutraceuticals through hospitals and a consumer distribution base through Korean off-line channels such as Holland & Barrett stores, hypermarkets, home-shopping, and e-commerce channels including on-line malls, open markets, influencer markets and live commerce markets.

 

This agreement with Inscobee is another milestone in a series of deals which ProBiotix have entered into within Asia which help build LP LDL® and CholBiome's reputation and brand awareness in the region and open up the potentail for cross boarder e-commerce trading in China. ProBiotix Health has substantial momentum in the region, according to a recent article published in Nutraingredient Asia: Probiotics and CVD: OptiBiotix extends CholBiome range to APAC as blood pressure and cholesterol concerns rise (nutraingredients-asia.com).

 

Mr. Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health commened: "Incobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets where consumers seek innovative and effective natural solutions which stand out in the market. We welcome Inscobee into a global team of CholBiome® distributors serving medical doctors and cardiovascular specialists and directly to consumers via homeshopping, pharmacies and medical clinics. By entering deals on CholBiome® and LP LDL® in India, China, Malaysia, Singapore, Indonesia, Phillipines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets."

 

Mr. Seung-Hyeon Nam, Director of Inscobee Plc, commented: "At Inscobee, we are very pleased to introduce CholBiome® products to the Korean healthcare market. We believe CholBiome® has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation and expect that it will play a big role as a flaghship product of Inscobee's healthcare business. We look forward to a long and successful partnership with ProBiotix Health."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

 

 

 

 

   

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUMWMUPGGQA
Date   Source Headline
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
5th Jun 20152:32 pmRNSExercise of Warrants and Issue of Equity
3rd Jun 20155:50 pmRNSHolding(s) in Company
2nd Jun 20157:00 amRNSContract with multinational consumer goods company
29th May 20157:00 amRNSFinal Results
28th May 20157:00 amRNSNew patent filings
26th May 20157:01 amRNSExercise of Warrants and Issue of Equity
15th May 20153:22 pmRNSHolding(s) in Company
13th May 20157:00 amRNSNotice of Results
21st Apr 20152:24 pmRNSExercise of Warrants and Issue of Equity
17th Apr 20157:00 amRNSResearch Update
14th Apr 20157:00 amRNSUK Investor Show attendance
10th Apr 20154:35 pmRNSPrice Monitoring Extension
8th Apr 20155:26 pmRNSHolding(s) in Company
31st Mar 20155:32 pmRNSGrant of Options
25th Mar 201512:54 pmRNSHolding(s) in Company
20th Mar 201510:32 amRNSExercise of Warrants and Issue of Equity
10th Mar 20157:02 amRNSContract signed with NIZO Food Research
23rd Feb 20157:00 amRNSInvestor Teach In
18th Feb 20157:00 amRNSBoard Appointment
4th Feb 20154:03 pmRNSHolding(s) in Company
21st Jan 20157:00 amRNSJoint venture with Nizo Food Research
20th Jan 20153:23 pmRNSExercise of Warrants and Issue of Equity
15th Jan 20157:00 amRNSAdditions to Scientific Advisory Group
9th Jan 20152:24 pmRNSExercise of Warrants and Issue of Equity
15th Dec 20147:00 amRNSCompletion of ethics approval & study recruitment
10th Dec 20147:00 amRNSChange of Adviser
2nd Dec 20147:00 amRNSSuccessful completion of pre-clinical studies
28th Nov 20142:34 pmRNSHolding(s) in Company
28th Nov 20147:00 amRNSProduct showcased at Health Ingredients Europe
27th Nov 20144:57 pmRNSExercise of Warrants
25th Nov 20147:00 amRNSAppointment of Non-Executive Director
18th Nov 20147:00 amRNSAppointment of Head of Research
14th Nov 20142:46 pmRNSIssue of Equity
11th Nov 20147:00 amRNSContract Signed to Start Clinical Studies
28th Oct 20147:00 amRNSIncorporation of Weight Management Formulation
20th Oct 20147:00 amRNSScientific Advisory Group
1st Oct 20144:08 pmRNSExercise of Warrants
17th Sep 20147:00 amRNSContract signed with Nizo Food Research
5th Aug 20147:00 amRNSFirst day of dealings on AIM
4th Aug 20143:27 pmRNSChange of Name
4th Aug 201411:19 amRNSResult of General Meeting
18th Jul 20144:08 pmRNSExercise of Warrants and Issue of Equity
18th Jul 20147:30 amRNSSchedule 1 - Ducat Ventures plc
18th Jul 20147:30 amRNSRestoration - Ducat Ventures plc
18th Jul 20147:00 amRNSPublication of Admission Document & Restoration...
18th Jul 20147:00 amRNSHalf Yearly Results
9th May 201411:05 amRNSTemporary Suspension
9th May 201411:03 amRNSSuspension - Ducat Ventures Plc
24th Feb 20142:54 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.